Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...
Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short
Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Pros and cons of weight-loss jabs
Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...
Gillingham charity boss hails weight-loss injections including Ozempic, Wegovy and Mounjaro as life-changing after dropping 6st in two months
A charity boss who struggled for years to shed pounds despite having undergone surgery has hailed weight-loss jabs as ...